Homologous Recombination Deficiency clinical trials at UCSF
1 research study open to eligible people
Homologous recombination deficiency happens when DNA repair is faulty. UCSF is conducting research to check the safety of the drug MOMA-313 for patients with advanced cancer. The trial focuses on understanding how well patients tolerate different doses of the drug.
Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
San Francisco, California and other locations
Last updated: